{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:31:38Z","timestamp":1793298698292,"version":"4.5.0"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,1,1]]},"DOI":"10.1097\/qai.0b013e3182a9b3f1","type":"journal-article","created":{"date-parts":[[2013,9,5]],"date-time":"2013-09-05T09:17:46Z","timestamp":1378372666000},"page":"72-77","source":"Crossref","is-referenced-by-count":22,"title":["Effect of Protease Inhibitors on Steady-State Pharmacokinetics of Oral Norethindrone Contraception in HIV-Infected Women"],"prefix":"10.1097","volume":"65","author":[{"given":"Jessica","family":"Atrio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank Z.","family":"Stanczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Neely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh","family":"Cherala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Kovacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Mishell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-10-20210131","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.contraception.2010.02.015","article-title":". Guidance on medical eligibility criteria for contraceptive use: identification of research gaps.","volume":"82","author":"Folger","year":"2010","journal-title":"Contraception"},{"key":"R5-10-20210131","first-page":"1","article-title":"Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Atlanta, GA: U.S. Department of Health and Human Services.","volume":"2012","year":"","journal-title":"Federal"},{"key":"R11-10-20210131","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/00003088-200038010-00003","article-title":"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.","volume":"38","author":"Dresser","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"R12-10-20210131","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.contraception.2009.03.014","article-title":"14 million women with limited options.","volume":"80","author":"Stuart","year":"2009","journal-title":"Contraception"},{"key":"R15-10-20210131","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jsbmb.2007.09.025","article-title":". Identification of the human cytochrome P450 enzymes involved in the in vitro biotransformation of linestrenol and norethindrone.","volume":"110","author":"Korhonen","year":"2008","journal-title":"J Steroid Biochem Mol Biol"},{"key":"R16-10-20210131","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01213011-200501000-00001","article-title":". Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients.","volume":"15","author":"Rotger","year":"2005","journal-title":"Pharmacogenet Genomics"},{"key":"R17-10-20210131","doi-asserted-by":"crossref","first-page":"730","DOI":"10.2174\/138920009789895534","article-title":". Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6.","volume":"10","author":"Mo","year":"2009","journal-title":"Curr Drug Metab"},{"key":"R19-10-20210131","first-page":"1","article-title":"U.S. Medical Eligibility Criteria for Contraceptive Use, 2010.","volume":"59","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"R21-10-20210131","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/0010-7824(78)90046-X","article-title":": A radioimmunoassay for norethindrone (NET): measurement of serum NET concentrations following ingestion of NET-containing oral contraceptive steroids.","volume":"18","author":"Stanczyk","year":"1978","journal-title":"Contraception"},{"key":"R22-10-20210131","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/S0002-9378(11)90772-8","article-title":": Single and multiple dose pharmacokinetics of a low dose oral contraceptive in women with chronic renal failure undergoing peritoneal dialysis.","volume":"168","author":"Price","year":"1993","journal-title":"Am J Obstet Gynecol"},{"key":"R23-10-20210131","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/FTD.0b013e31825c4ba6","article-title":". Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R.","volume":"34","author":"Neely","year":"2012","journal-title":"Ther Drug Monit"},{"key":"R24-10-20210131","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-2265.1979.tb03030.x","article-title":". Plasma levels of norethindrone after single oral dose administration of norethindrone and lynestrenol.","volume":"10","author":"Odlind","year":"1970","journal-title":"Clin Endocrinol (oxf)"},{"key":"R30-10-20210131","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1016\/0002-9378(71)90624-7","article-title":"Continuous norethindrone, 0.35 mg, as an oral contraceptive agent.","volume":"109","author":"Board","year":"1971","journal-title":"Am J Obstetrics Gynecol"},{"key":"R31-10-20210131","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1136\/bmj.2.5600.266","article-title":". Effect of oral continuous progestogen therapy in microdosage on human ovary and sperm transport.","volume":"2","author":"Zanartu","year":"1968","journal-title":"Br Med J"},{"key":"R32-10-20210131","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1530\/jrf.0.0130199","article-title":". Assay of the anti-oestrogenic effects of progestagens in women.","volume":"13","author":"Rudel","year":"1967","journal-title":"J Reprod Fertil"},{"key":"R33-10-20210131","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1136\/bmj.2.5659.730","article-title":". Preliminary evaluation of four oral contraceptives containing only progestogens.","volume":"2","author":"Mears","year":"1969","journal-title":"Br Med J"},{"key":"R34-10-20210131","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1136\/bmj.2.5554.730","article-title":". Daily progestogen for contraception: a clinical study.","volume":"2","author":"Martinez-Manautou","year":"1967","journal-title":"Br Med J"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/QAI.0b013e3182a9b3f1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T06:04:14Z","timestamp":1620972254000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00126334-201401010-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,1]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e3182a9b3f1","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1,1]]}}}